Abstracts tagged "canakinumab and juvenile idiopathic arthritis (JIA)"

Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…
Abstract Number: 44 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut⁴, Katherine Marzan⁵, Nico Wulffraat², Rayfel Schneider⁵, Shai Padeh⁶, Vyacheslav Chasnyk⁶, Carine Wouters⁶, Jasmin B. Kuemmerle-Deschner⁶, Tilmann Kallinich⁶, Bernard Lauwerys⁷, Elie Haddad⁵, Evgeny L Nasonov⁶, Maria Trachana⁶, Olga Vougiouka⁶, Karolynn Leon⁸, Eleni Vritzali⁹, Karine Lheritier¹⁰, Alberto Martini⁶ and Daniel Lovell⁵, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁵PRCSG, Cincinnati, OH, ⁶PRINTO-Istituto Gaslini, Genova, Italy, ⁷Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN) demonstrated…